Product Pipeline

Clinical Applications

Research to seek new medical uses and/or novel modes of administration for our specialty products.

C1-INH New indications

Research on novel indications using C1-esterase inhibitor (C1-INH).

Fibrinogen New Formulations

Research and pre-clinical studies to seek additional medical uses for plasma-derived Fibrinogen concentrate

CSL964 AAT GvHD

Prevention of acute Graft versus Host Disease (GVHD) in high-risk adolescent and adult patients receiving an allogeneic hematopoietic cell transplant (HCT). Treatment of steroid refractory acute GVHD in adolescent and adult patients

CSL842 C1-INH AMR

C1-esterase inhibitor (C1-INH) for the treatment of refractory antibody mediated rejection (rAMR) in adult renal transplant recipients.

Privigen® Japan

Privigen®, 10% intravenous immunoglobulin, for the treatment of primary immune deficiency (PID), secondary immune deficiency (SID) and chronic inflammatory demyelinating polyneuropathy (CIDP) indications in Japan.

Hizentra® IIM

Hizentra™, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Idiopathic Inflammatory Myopathies (IIM).

Privigen® CIDP Japan

Privigen®, 10% intravenous immunoglobulin, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.

Hizentra® CIDP

The first 20% high concentration low volume subcutaneous immunoglobulin for convenient self administration. Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Privigen® CIDP US

Privigen®, 10% intravenous immunoglobulin, approved for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.

CSL830 EU

The first and only self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.

Kcentra® Japan

Lyophilized formulation of plasma-derived concentrate of coagulation factors II, VII, IX, X, Protein C and Protein S used as intravenous administration in patients with acquired deficiency of coagulation factors due to vitamin K antagonist (e.g. Warfarin) therapy.

HAEGARDA® US

The first and only self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.

AFLURIA® QIV 5+ US, AUS

Seasonal egg-based quadrivalent influenza vaccine offering protection against four different strains

FLUAD® aTIV 65+ UK, AUS

Seasonal egg-based adjuvanted trivalent influenza vaccine offering protection against three different strains

FLUCELVAX® QIV 4+ US

Seasonal cell culture-based quadrivalent influenza vaccine offering protection against four different strains

Emerging Technologies

Research to investigate emerging technologies to develop novel treatments for patients receiving Immunoglobulins.

CSL889 Hemopexin

Research program on plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease.

Novel Strategies

Research activities to develop novel coagulation factors with improved efficacy and enhanced convenience.

CSL626 D'D3 LA rVIII

Recombinant D’D3 albumin fusion protein dimer (rD’D3-FP), which prolongs the in vivo half-life and thereby increases the dosing interval of rVIII-SingleChain in hemophilia A patients to at least once per week.

Discovery Projects

Research projects aiming to develop novel therapeutic proteins.

CSL200/CAL-H

Ƴ-Globin Gene Therapy for Severe Sickle Cell Disease (SCD).

CSL311 Anti-Beta Common

Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases.

Clinical Applications

Research projects aiming to build a new leading franchise in Transplant therapeutics

CSL334 IL-13R* ASLAN

Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis, asthma and other indications. Licensed to ASLAN Pharmaceuticals.

* Partnered Project

P. gingivalis POD OH-CRC

Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis.

SAM Influenza Vaccine

Influenza Vaccine development using novel mRNA-based technology.

CSL730 rFc Multimer

Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals.

CSL312 FXIIa Antagonist

A humanised anti-factor XIIa monoclonal antibody in development for use in multiple indications including as a subcutaneous therapy for HAE with the potential for administration once every two to three weeks and potential applications in Thrombosis.

CSL324 G-CSFR Antagonist

Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.

CSL346 VEGFB Antagonist

A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.

CSL112 Apo-A1

Novel apolipoprotein A-I infusion therapy developed to reduce the high incidence of early recurrent cardiovascular events that occur in the weeks to months following a heart attack.

Mavri GM-CSFR-AZ*

Recombinant monoclonal antibody inhibiting GM-CSF activity by targeting the GM-CSF receptor for use in rheumatoid arthritis. Licensed to Astra Zeneca. Multiple Phase IIb studies in progress.

* Partnered Project

clazakizumab* Transplant

Humanized recombinant monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6) as a therapeutic option for solid organ transplant rejection. Development in collaboration with Vitaeris Inc.

* Partnered Project

pdFVIII Ruide

Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).

IDELVION®

Novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. Delivers high-level protection with up to 14-day dosing in appropriate patients.

AFSTYLA®

Novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.